However, oxaliplatin in adjuvant chemotherapy regimens has unexpectedly been reported to activate mTOR signaling in response to chemotherapy resistance, suggesting a biological response of cancer cells to the cell-killing mechanism of anti-cancer drugs [15]. This evidence concerns the gene MTOR and cancer.